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The authors sought to better understand the combined effects of pretransplant, transplant, and post-
transplant factors in determining risks of serious cardiovascular disease after hematopoietic cell trans-
plantation (HCT). Hospitalizations and deaths associated with serious cardiovascular outcomes were
identiﬁed among 1379 Washington State residents who received HCT (57% allogeneic and 43% autologous) at
a single center from 1985 to 2005, survived  2 years, and followed through 2008. Using a nested case-cohort
design, relationships (hazard ratios [HRs]) between potential risk factors and outcomes were examined
among affected survivors and a randomly selected subcohort (N ¼ 509). After 7.0 years of median follow-up
(range, 2.0 to 23.7), the 10-year cumulative incidence of ischemic heart disease, cardiomyopathy, stroke, and
all-cause cardiovascular death was 3.8%, 6.0%, 3.5%, and 3.7%, respectively. In multivariable analysis, increased
pretransplant anthracycline was associated with cardiomyopathy. Active chronic graft-versus-host disease
was associated with cardiovascular death (HR, 4.0; 95% conﬁdence interval, 1.1 to 14.7); risk was otherwise
similar between autologous versus allogeneic HCT recipients. Independent of therapeutic exposures, pre-
transplant smoking, hypertension, dyslipidemia, diabetes, and obesity conferred additional risk of all out-
comes except stroke (HR  1.5 for each additional risk factor, P < .03). Hypertension and dyslipidemia at 1
year with persistence of these conditions 2 or more years after HCT also were associated with independent
risks of multiple outcomes. HCT survivors with preexisting or newly developed and persistent cardiovascular
risk factors remain at greater risk of subsequent serious cardiovascular disease compared with other survi-
vors, independent of chemo- and radiotherapy exposures. These survivors should receive appropriate follow-
up and be considered for primary intervention.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION in determining subsequent risk of ischemic heart disease,
More than 60,000 patients receive some form of alloge-
neic or autologous hematopoietic cell transplantation (HCT)
annually worldwide [1]. Although chronic graft-versus-host
disease (GVHD) and disease recurrence remain the leading
causes of mortality in long-term HCT survivors [2-4], in-
vestigators have recognized the increased risk of long-term
cardiovascular and other morbidities in HCT survivors
compared with the general population [5-11]. Although
many HCT recipients receive chemotherapy and radio-
therapy that affect cardiovascular health before HCT, few
studies have examined the inﬂuence of pretransplant expo-
sures in combinationwith transplant-related factors [12-14].
The goal of this nested case-cohort study was to measure
the relative contributions of selected pretransplant thera-
peutic exposures and known cardiovascular risk factors
(obesity, hypertension, dyslipidemia, diabetes, smoking) in
combination with transplant and post-transplant exposuresedgments on page 799.
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14.02.012cardiomyopathy/heart failure, stroke, and all-cause cardio-
vascular death among  2-year HCT survivors. Speciﬁcally,
we wanted to investigate the importance of early manifes-
tations of post-transplant obesity, hypertension, dyslipide-
mia, and diabetes. This information would inform the
development of more appropriate screening and interven-
tion among HCT survivors, including earlier identiﬁcation of
at-risk patients [15,16].
METHODS
Patient Population and Outcomes Ascertainment
The original cohort and method for outcomes ascertainment were
described previously [9]. Brieﬂy, eligible HCT recipients were Washington
State residents treated at the Fred Hutchinson Cancer Research Center
(FHCRC) from 1985 to 2005 and alive  2 years post-HCT (N ¼ 1405). FHCRC
is a National Cancer Instituteedesignated comprehensive cancer center and
the only accredited institution that performs allogeneic HCT in Washington
State. Study procedures were approved by the institutional review boards at
FHCRC and the Washington State Department of Health. After excluding
residents who emigrated out-of-state within 2 years after HCT (n ¼ 19) and
those who withdrew consent for future research (n ¼ 7), 1379 survivors
were available for analysis.
Primary outcomes (Supplemental Table 1) were ischemic heart disease
(acute myocardial infarct, coronary artery bypass/angioplasty or related ther-
apeutic interventions, atherosclerotic heart disease, and angina/chronic
ischemic heart disease), cardiomyopathy/heart failure (including need for
heart transplant/assist device), stroke (cerebrovascular accident, intracranialTransplantation.
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plasty or related interventions), and any cardiovascular death occurring  2
yearsafter the indexHCT, asascertainedby the statehospitaldischarge registry
and thestatedeath registry throughDecember31,2008.Thehospitaldischarge
registry included all discharges from non-Federal facilities statewide, with up
to 9 diagnosis and 5 procedure codes (International Classiﬁcation of Diseases,
9th revision)perhospitalization. Thedeath registry records theprimaryandup
to 6 contributing causes of death (International Classiﬁcation of Diseases,10th
revision) and includes deaths ofWashington residentswhodie in neighboring
states. FHCRC records, including health surveys mailed annually to all HCT
survivors, also were reviewed because cardiomyopathy/heart failure may
present less acutely and not be associatedwith hospitalization comparedwith
our other outcomes of interest. This review identiﬁed 3 additional residents
with clinically documented heart failure not ascertained by administrative
data. Persons could experience more than 1 outcome, but only the ﬁrst
occurrence for any given outcome was counted.
Nested Case-Cohort Study
Given limited resources and the detailedmedical record review required
for exposure assessment, we used a nested case-cohort study design. In
contrast to a nested case-control study, this design allows for analyses of
multiple outcomes while using only a representative subset of the entire
cohort without a need to select different comparison groups for each
outcome [17]. A subset of the cohort (509 of 1379) was randomly selected to
provide approximately 10 comparison subjects per case; comparison sub-
jects do not need to be selected on the basis of any a priori matching criteria
in a case-cohort study [17]. In the analysis of each outcome, we used this
randomly selected subcohort plus all additional subjects within the overall
cohort who developed the speciﬁc outcome of interest. Thus, the numbers
available for analysis varied for different outcomes, ranging from 525 for
stroke to 544 for cardiomyopathy (Figure 1). Overall, records of 629 survi-
vors were reviewed in detail. Subjects with a history of ischemic heart
disease (n ¼ 11), cardiomyopathy (n ¼ 9), or stroke (n ¼ 5) before HCT were
excluded from the analysis of each respective outcome.
Exposure Ascertainment
Pretransplant exposures ascertained from medical records included
anthracyclines, radiotherapy, smoking history (never, any, and current), and
baseline medication use for hypertension, dyslipidemia, or diabetes.
Anthracycline doses were converted to the equivalent doxorubicin dose:
daunorubicin  .83, epirubicin  .67, idarubicin  5, and mitoxantrone  4
[18]. Radiotherapy records were abstracted and exposures classiﬁed by
the body area exposed: brain, chest, and abdomen/pelvis. Fields that span-
ned multiple body areas (eg, spine) had all relevant areas coded as exposed.
Self-reported race/ethnicity, clinically recorded body mass index (BMI)
at the time of transplantation, and selected transplant-related exposures
(donor type, stem cell source, and conditioning regimen including total body
or lymphoid irradiation) were obtained from the FHCRC transplant database.
BMI was categorized as <18.5, 18.5 to 24, 25 to 29, and 30 kg/m2, corre-
sponding to underweight, normal, overweight, and obese, respectively. For
subjects ages 2 to 20 years, we used corresponding categories based on age-Figure 1. CONSORT diagram outlining the analytic poand sex-standardized BMI percentiles [19]. All radiotherapy records were
reviewed (by E.C. and K.W.), and the cumulative average cardiac dose from
all pretransplant and transplant-related exposures was estimated based on
available treatment records and comparisonwith sex and body sizematched
re-created 3-dimensional radiation plan models [20].
Post-transplant exposures such as duration of systemic immunosup-
pressive therapy for chronic GVHD, BMI at 1 year post-HCT, and use of
medications for hypertension, dyslipidemia, and diabetes throughout the
entire post-HCT period were abstracted from the medical records. We also
examined available total cholesterol, triglyceride, and glucose values 1 year
after HCT among patients who returned to FHCRC for follow-up; these are
typically requested to be fasting.
Statistical Analysis
Chi-square and Wilcoxon rank sum tests were used to test for differ-
ences among proportions and non-normally distributed continuous out-
comes. We used multivariable proportional hazards models to calculate
hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for each of the 4
outcomes, starting 2 years after HCT. Primary models adjusted for de-
mographic characteristics (sex, age at and year of HCT, and non-Hispanic
White race/ethnicity versus other), anthracycline dose (none, <200, 200
to 299,300mg/m2), cardiac radiation dose including total body irradiation
(TBI; <1, 1 to 19, 20 Gy), any radiotherapy exclusive of TBI to the brain or
abdomen/pelvis (yes/no), TBI dose separately (<10/10 Gy), donor type
(autologous, related allogeneic, unrelated allogeneic), chronic GVHD (none,
active, resolved), and any relapse of one’s primary disease after HCT (yes/
no). Relapse and chronic GVHD were modeled as separate time-dependent
covariates. In lieu of cardiac radiotherapy dose, any chest radiotherapy other
than TBI also was examined with similar results.
Secondary models examined any additional inﬂuence of the following
pre-HCT factors added to the primary models: BMI at time of HCT (normal/
underweight, overweight, obese), current smoking (yes/no), and medica-
tions for hypertension, dyslipidemia, or diabetes (each yes/no). The
inﬂuence of BMI 1 year post-transplant also was examined, along with post-
transplant use of medications for hypertension, dyslipidemia, and/or
diabetes as time-dependent covariates. Given our case-cohort study design,
we used robust variance estimators for all models [21]. For the 4 outcomes
examined, we only counted the ﬁrst occurrence of that speciﬁc outcome;
follow-up was otherwise censored at December 31, 2008, or when patients
migrated out of state. Death from causes other than the speciﬁc outcome
examinedwas treated as a competing risk event [22]. Given the possibility of
introducing bias and losing precision with overly adjusted models, we also
examined simpler models with at least 5 events per covariate, with overall
similar results [23]. Analyses were performed using Stata version 12 (Sta-
taCorp, College Station, TX).
RESULTS
Baseline demographic and HCT-related characteristics
were similar between the full study cohort and the randomly
selected subcohort (Table 1). Among the subcohort, thepulation used for the nested case-cohort study.
Table 1
Demographic and Treatment Characteristics of the Study Cohort and the
Randomly Selected Subcohort
Characteristic* Cohort
(N ¼ 1379)
Subcohort
(N ¼ 509)
P
Female 653 (47.4) 238 (46.8) .84
Age at transplant, yr .79
<20 302 (21.9) 110 (21.6)
20-39 360 (26.1) 144 (28.3)
40-59 604 (43.8) 217 (42.6)
60 113 (8.2) 38 (7.5)
Year of transplant .27
1985-1994 365 (26.5) 150 (29.5)
1995-2000 450 (32.6) 170 (33.4)
2001-2005 564 (40.9) 189 (37.1)
Race/ethnicity .85
White, non-Hispanic 1161 (84.2) 436 (85.7)
Black 30 (2.2) 11 (2.2)
Hispanic 64 (4.6) 23 (4.5)
Asian/Paciﬁc Islander 39 (2.8) 9 (1.8)
Other 19 (1.4) 8 (1.6)
Unknown 66 (4.8) 22 (4.3)
Underlying diagnosis .63
Acute leukemia, myelodysplastic
syndrome
443 (32.1) 184 (36.1)
Chronic leukemia 206 (14.9) 67 (13.2)
Lymphoma 305 (22.1) 106 (20.8)
Multiple myeloma 169 (12.3) 53 (10.4)
Breast cancer 77 (5.6) 34 (6.7)
Neuroblastoma 50 (3.6) 18 (3.5)
Other solid tumor 35 (2.5) 9 (1.8)
Nonmalignant blood disorder 51 (3.7) 22 (4.3)
Immune/metabolic disease 25 (1.8) 7 (1.4)
Multiple/systemic sclerosis 18 (1.3) 9 (1.8)
Pretransplant exposuresy
Alkylating agent d 277 (54.5)
Anthracycline, mg/m2
None d 151 (29.8)
<200 d 124 (24.5)
200-299 d 80 (15.8)
300 d 151 (29.8)
Radiotherapy
Brain d 18 (3.5)
Neck d 35 (6.9)
Spine d 24 (4.7)
Chest d 53 (10.4)
Abdomen/pelvis d 41 (8.1)
Prior total body/lymphoid d 3 (.6)
Stem cell donor .70
Autologous 599 (43.4) 218 (42.8)
Related allogeneic 491 (35.6) 191 (37.5)
Unrelated allogeneic 289 (21.0) 100 (19.6)
Stem cell sourcez .53
Marrow 584 (42.3) 220 (43.2)
Peripheral blood 819 (59.4) 297 (58.3)
Cord blood 12 (.9) 2 (.4)
Transplant conditioning regimenx
No TBI 736 (53.4) 260 (51.1) .54
TBI, 1-9 Gy 102 (7.4) 35 (6.9)
TBI, 10Gy 541 (39.2) 214 (42.0)
Cyclophosphamide/TBI 413 (29.9) 165 (32.4) .30
Busulfan/cyclophosphamide 263 (19.1) 84 (16.5) .20
Chronic GVHD 483 (35.0) 175 (34.4) .79
Resolved at last follow-upy,k e 113 (22.2)
Post-transplant relapse 359 (26.0) 146 (28.7) .25
Relapse within 2 years of transplant 217 (15.7) 86 (16.9)
Died, any causek 353 (25.6) 146 (28.7) .18
Values are number of cases, with percents in parentheses.
* Proportions shown based on those without missing data.
y Only determined for subcohort.
z Exceeds totals because some individuals had mixed products as part of
single or tandem transplants.
x Categories are not mutually exclusive.
k As of December 31, 2008.
E.J. Chow et al. / Biol Blood Marrow Transplant 20 (2014) 794e800796median age at time of HCT was 40 years (range, 0 to 69), with
a median follow-up of 7.0 years (range, 2.0 to 23.7). After
accounting for out-of-state migration  2-years post-HCT
(n ¼ 17) and death (n ¼ 144), 348 subjects (68.4%)
remained alive as of December 31, 2008. Most subcohort
subjects were treated for hematologic malignancies (80.6%),
and most had received prior alkylating agents (54.5%) or
anthracyclines (70.2%), although few had received any
radiotherapy before HCT (eg, 10.4% prior chest exposure).
Most received an allogeneic transplant (57.2%), with 60.1% of
allogeneic recipients requiring subsequent systemic immu-
nosuppressive therapy for chronic GVHD. Nearly half (48.9%)
received some form of TBI-based conditioning for HCT; all
TBI doses were fractionated. Inclusive of TBI, 8.5% of the
subcohort received an average of 1 to 9 Gy to the heart, 45.2%
received 10 to 19 Gy, 2.6% received 20 to 29 Gy, and 2.0%
received 30 Gy.
Between time of transplant and 1 year later, rates of
obesity and use of lipid-lowering medications remained
stable (22.9% versus 21.0% and 3.0% versus 2.8%, respectively;
Table 2), but use of antihypertensives and diabetes medica-
tions was much more frequent at 1 year post-HCT (6.7%
versus 19.6% and 4.1% versus 12.9%). The proportion of sur-
vivors on hypertension and lipid-lowering medications
increased further by time of last follow-up, although 34 of 65
patients on diabetes medications at 1 year post-HCT had
discontinued treatment by time of last follow-up. Rates of
chronic GVHD did not differ signiﬁcantly among subjects
who discontinued treatment for hypertension, dyslipidemia,
and diabetes between 1 year and last follow-up compared
with those who remained on treatment (data not shown).
Among survivors with data available 1 year after HCT,
10.8% (29 of 268) had glucose  126 mg/dL, and the pro-
portions with total cholesterol  240 mg/dL and triglyceride
 150 mg/dL were even greater (28.2% and 58.0%, respec-
tively; n¼ 241). The proportions were similar after excluding
patients taking diabetes and/or lipid-lowering medications:
8.6%, 28.5%, and 57.8%, respectively. Overall, subjects with
laboratory data were more likely to have been transplanted
inmore recent years and to reﬂect the populationmore likely
to return to the transplant center for an in-person evaluation
(allogeneic versus autologous HCT and, among allogeneic
recipients, those with a history of chronic GVHD).
Overall, 135 individuals (9.8%) experienced at least 1 of
the serious cardiovascular complications ascertained by this
study. The 10-year cumulative incidence of serious cardio-
vascular disease associated with hospitalization/death
ranged from 3.5% (stroke) to 6.0% (cardiomyopathy;
Figure 1). The median time from HCT to onset of these
complications was 5.0 years (range, 2.0 to 20.7).
In multivariable analyses, increased anthracycline dose
was associated with cardiomyopathy (Table 3). Radiotherapy,
including cardiac radiation, was not signiﬁcantly associated
with any adverse outcome, although estimates were impre-
cise. Among transplant-related exposures, having active
chronic GVHD was associated with an increased risk of car-
diovascular death (HR, 4.0; 95% CI, 1.1 to 14.7), although the
relative hazard was attenuated after GVHD resolution. Nine
of the 12 cardiovascular deaths among individuals with
active chronic GVHD listed codes consistent with underlying/
chronic heart disease. Finally, any history of original disease
relapse after HCT was associated with a signiﬁcantly
Table 2
Distribution of Pre- and Post-Transplant Cardiovascular Risk Factors among
Subcohort (N ¼ 509*)
Trait Pretransplant 1-Year Post-
Transplant
Last
Follow-Up
History of tobacco usey 171 (33.8) d d
Current user 49 (9.7) d d
Body mass index,z kg/m2
Underweight, <18.5 11 (2.2) 21 (4.3) d
Normal, 18.5-24 206 (41.4) 224 (46.2) d
Overweight, 25-29 167 (33.5) 138 (28.5) d
Obese, 30 114 (22.9) 102 (21.0) d
Hypertension treatment 34 (6.7) 98 (19.6) 119 (23.9)
On treatment at prior
time point, still on
d 28 (5.6) 63 (12.7)
Off treatment at prior
time point, now on
d 70 (14.0) 56 (11.2)
On treatment at prior
time point, now off
d 6 (1.2) 34 (6.8)
Dyslipidemia treatment 15 (3.0) 14 (2.8) 79 (15.8)
On treatment at prior
time point, still on
d 7 (1.4) 13 (2.6)
Off treatment at prior
time point, now on
d 7 (1.4) 64 (12.8)
On treatment at prior
time point, now off
d 8 (1.6) 1 (.2)
Diabetes treatment 21 (4.1) 65 (12.9) 54 (10.7)
On treatment at prior
time point, still on
d 21 (4.2) 31 (6.2)
Off treatment at prior
time point, now on
d 44 (8.7) 23 (4.6)
On treatment at prior
time point, now off
d 0 34 (6.7)
Values are number of cases, with percents in parentheses.
* Percentages based on those with data among the subcohort (depending
on the risk factor and time point, n ¼ 498 to 509).
y Only assessed pretransplant.
z Limited to those ages  2 years. Values for survivors ages 2-20 years
based on equivalent age- and sex-speciﬁc percentiles. Only assessed pre-
transplant and 1-year post-transplant.
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ischemic heart disease, suggesting that relapse may be acting
as a surrogate marker for additional cardiotoxic exposures.Table 3
Relative Hazards of Cardiovascular Outcomes Associated with Pretransplant and T
Exposure HR (95% CI)
Cardiovascular Death Ischemic
Anthracycline,y mg/m2
None 1.0 (ref) 1.0 (ref)
<200 2.2 (.7-7.6) 1.0 (.4-2.
200-299 3.6 (.9-14.1) 1.2 (.3-4.
300 2.8 (.9-8.8) .8 (.3-2.
Brain radiotherapy vs. nonez 1.1 (.1-9.8) d
Abdomen radiotherapy vs. nonez 2.7 (.9-8.3) 1.8 (.7-4.
Cardiac radiotherapy dose,x Gy
<1 1.0 (ref) 1.0 (ref)
1-19 .3 (.1-1.3) .6 (.2-1.
20 1.4 (.4-5.3) 1.3 (.3-5.
TBI  10 Gy vs. less 1.4 (.3-6.9) 1.7 (.5-5.
Allogeneic vs. autologous donor 1.9 (.5-7.7) .6 (.2-2.
Chronic GVHD
None 1.0 (ref) 1.0 (ref)
Active 4.0 (1.1-14.7) 2.6 (.7-8.
Resolved 1.2 (.3-4.8) 2.2 (.8-6.
Original disease relapse vs. none 4.3 (1.9-9.6) 1.5 (.7-3.
Numbers in this table that are in bold are estimates that meet statistical signiﬁcan
* Estimates reﬂect adjustment for exposures shown plus sex, age at and year of
y In terms of doxorubicin equivalent dose.
z Brain and abdomen (including pelvis) ﬁelds exclusive of total body irradiation
x Inclusive of any TBI.Increased HRs were observed for most pretransplant
cardiovascular risk factors (smoking, obesity, hypertension,
diabetes), although individual CIs often did not meet statis-
tical signiﬁcance (Table 4). However, having an increasing
number of these adverse risk factors pretransplant was
associated with all subsequent cardiovascular complications
(HR  1.5 for each additional risk factor, P < .03) except
stroke. Estimates were similar even if smoking status was not
counted.
Having an increased number of these risk factors at 1 year
remained predictive of subsequent ischemic heart disease
(HR, 1.7; 95% CI, 1.1 to 2.7; Table 4). Compared with pre-
transplant estimates, HRs for multiple risk factors at 1 year
associated with cardiovascular death and cardiomyopathy
became attenuated. However, when only subjects who had
persistent conditions (ie, present both at 1 year and at last
follow-up) were classiﬁed as exposed, the magnitude of
resulting associations was increased, more similar to the
effect of having these conditions before HCT (Supplemental
Table 2).
Because most survivors with abnormal glucose, choles-
terol, and triglyceride values 1 year after HCT did not appear
to be receiving targeted treatment, we also examined
whether subjects who developed subsequent adverse car-
diovascular complications would have different values
compared with those who were unaffected and alive at last
follow-up (Supplemental Table 3). Excluding subjects
receiving concurrent lipid-lowering or diabetes medications,
those who developed cardiovascular disease generally had
greater total cholesterol and triglyceride median values. This
was most marked for ischemic heart disease (triglyceride
280 versus 160 mg/dL [3.16 versus 1.81 mmol/L], P ¼ .03;
cholesterol 213 versus 195 mg/dL [5.52 versus 5.05 mmol/L],
P ¼ .06).
Hypertension and diabetes  2-years post-HCT remained
important predictors of subsequent cardiovascular disease
(Table 4). Hypertension was signiﬁcantly associated with
increased risks of ischemic heart disease and cardiomyopa-
thy (HRs  2.8, P < .01), whereas diabetes was associated
with an increased risk of all-cause cardiovascular mortalityransplant-Related Therapeutic Exposures*
Heart Disease Cardiomyopathy/Heart Failure Stroke
1.0 (ref) 1.0 (ref)
5) 2.3 (.8-6.8) 1.6 (.5-4.6)
1) 3.3 (.8-13.2) .9 (.2-4.4)
2) 4.5 (1.5-13.3) 2.2 (.7-7.2)
.7 (.1-6.2) .7 (.1-4.2)
5) .8 (.3-2.4) .9 (.2-3.3)
1.0 (ref) 1.0 (ref)
7) .9 (.4-2.1) .6 (.2-2.1)
0) 1.3 (.4-4.7) .5 (.1-5.1)
3) 1.2 (.5-2.8) 1.0 (.2-3.6)
2) 1.2 (.4-3.4) 1.3 (.3-5.5)
1.0 (ref) 1.0 (ref)
9) 1.1 (.4-3.1) 1.7 (.4-7.0)
1) 1.4 (.5-3.9) 1.4 (.4-5.2)
2) 3.2 (1.7-6.0) 5.9 (2.4-14.7)
ce (P < 0.05).
transplant, and race/ethnicity.
.
Table 4
Relative Hazards of Cardiovascular Outcomes Associated with Presence of Pre- And Post-Transplant Cardiovascular Risk Factors
Risk Factor HR (95% CI)
Cardiovascular
Death
Ischemic Heart
Disease
Cardiomyopathy/
Heart Failure
Stroke
Pretransplant*
Current smoking vs. none 2.7 (.8-9.2) 2.3 (.95-5.4) 1.8 (.6-5.1) .4 (.04-3.8)
Obese vs. normal/underweight 1.5 (.6-4.0) 2.0 (.8-4.9) 1.2 (.5-2.9) 1.5 (.5-4.3)
Hypertension treatment vs. none .8 (.1-4.0) 2.3 (.6-8.9) 1.5 (.6-3.7) 4.8 (1.1-21.0)
Dyslipidemia treatment vs. none 3.8 (1.0-14.4) 1.8 (.4-8.1) 3.2 (.7-14.9) 1.4 (.2-11.2)
Diabetes treatment vs. none 3.3 (.6-17.4) 2.7 (.8-10.0) 1.5 (.5-4.8) .6 (.1-6.1)
Risk associated with presence of each additional risk factory 1.8 (1.2-2.8) 2.1 (1.4-3.1) 1.5 (1.1-2.2) 1.3 (.7-2.2)
1-Year post-transplant*
Obese vs. normal/underweight 1.7 (.6-4.8) 2.0 (.8-4.9) .6 (.2-1.5) 1.4 (.5-3.6)
Hypertension treatment vs. none 1.9 (.6-5.8) 2.2 (.7-6.6) 3.8 (1.4-8.6) 2.2 (.9-5.8)
Dyslipidemia treatment vs. none 2.0 (.3-16.3) 3.6 (.7-18.0) 1.0 (.1-8.3) 7.4 (1.2-47.0)
Diabetes treatment vs. none 1.3 (.4-4.2) 1.2 (.4-3.4) 1.4 (.5-3.8) .1 (.02-.8)
Risk associated with presence of each additional risk factorz 1.6 (.97-2.6) 1.7 (1.1-2.7) 1.2 (.8-1.8) 1.2 (.7-2.2)
If restricted to those with risk factor also present at last follow-upz 1.9 (1.1-3.1) 2.2 (1.4-3.7) 1.3 (.9-2.0) 1.7 (.98-2.9)
2-Year post-transplantx
Hypertension treatment vs. none 1.4 (.5-3.9) 3.6 (1.7-7.6) 2.8 (1.3-5.7) 1.8 (.8-4.0)
Dyslipidemia treatment vs. none 2.1 (.8-5.5) 1.1 (.4-3.0) 1.8 (.8-4.4) 1.9 (.6-5.4)
Diabetes treatment vs. none 3.5 (1.3-9.6) 2.8 (1.0-7.9) 1.5 (.5-4.6) .9 (.2-3.3)
Numbers in this table that are in bold are estimates that meet statistical signiﬁcance (P < 0.05).
* Models included factors examined in Table 3, plus concurrent adjustment of factors listed below.
y Trend test for 0, 1, 2, and 3 risk factors including tobacco use, obesity, hypertension, dyslipidemia and diabetes.
z Trend test for 0, 1, 2, and 3 risk factors including obesity, hypertension, dyslipidemia and diabetes.
x Models included all factors examined in Table 3, plus concurrent adjustment of factors listed below as time-dependent variables.
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mates for dyslipidemia were not statistically signiﬁcant,
although they generally indicated increased risk. In these
time-dependent models, we did not observe any secular ef-
fect associated with any of our outcomes, except for a
decreased risk of cardiovascular death among patients
transplanted in later years (HR, .3 to .4 for 1990 to 1999 and
2000 to 2005 compared with pre-1990, P < .05).
DISCUSSION
Our prior analysis compared the incidence rates of major
cardiovascular complications among this cohort of greater
than 1300 HCT survivors with a matched general population
sample from the same geographic region [9]. In that studywe
found that HCT survivors had a signiﬁcantly greater cumu-
lative incidence of cardiovascular complications, including
conditions such as hypertension, dyslipidemia, and diabetes.
That study was limited by lack of information on pretrans-
plant treatment and the temporal relationship of hyperten-
sion, dyslipidemia, and diabetes on subsequent risk of
cardiovascular disease. We extended that work here by
additionally considering important therapeutic and
nontherapeutic exposures along the entire treatment con-
tinuum, including detailed ascertainment of chronic GVHD,
hypertension, dyslipidemia, and diabetes status over time.
Our results underscore the important continued inﬂuence of
conventional risk factors on subsequent cardiovascular dis-
ease among heavily treated HCT survivors and provide
further insight into subsets of survivors who may beneﬁt
from additional intervention and prevention strategies.
Among pretransplant therapeutic exposures, our results
conﬁrm the known association between greater anthracy-
cline dose and cardiomyopathy [12,24,25]. Similar to some
other studies of HCT survivors, no associations between
cardiac radiotherapy and subsequent cardiomyopathy
[12,24] or other cardiovascular complications [5,7] were
observed. These results contrast with the well-documented
doseeresponse associations reported in other studies ofHCT and nontransplant cancer survivors [13,14,26-28].
However, most irradiated survivors in our study received
relatively low cardiac exposure (<5% of our subcohort
received  20 Gy to the heart), and our median follow-up
also was relatively short. Both factors likely limited our
ability to detect signiﬁcant differences.
There was no difference in risk of cardiovascular out-
comes between autologous or allogeneic recipients after
accounting for other treatment exposures and chronic GVHD
status. However, having active chronic GVHD was associated
with an increased risk of cardiovascular death. Chronic
GVHD, as a chronic inﬂammatory condition, has been hy-
pothesized to contribute to atherosclerotic disease [11,29],
and, importantly, immunosuppressants used to treat GVHD
(eg, glucocorticoids, calcineurin inhibitors, sirolimus) often
have cardiovascular side effects, including hypertension, in-
sulin resistance, renal dysfunction, and dyslipidemia [30]. In
other studies, even after accounting for effects of active
chronic GVHD and/or its treatment, allogeneic HCT survivors
still appear to have an increased risk of developing hyper-
tension, dyslipidemia, and diabetes that predispose toward
more serious cardiovascular disease compared with other
cancer survivors or the general population [6,11,14,31-34].
However, data from our study and others have shown that
although these cardiovascular risk factors develop frequently
after HCT, especially after allogeneic transplant, it appears
that many HCT survivors do not receive speciﬁc treatment for
these conditions [32,35,36]. Our reliance on medication
status to deﬁne cardiovascular risk factors in this study likely
underestimates the true prevalence of these condition,
perhaps because clinicians believe these conditions often
improve within 2 years among some transplant recipients,
especially after patients are tapered off chronic immuno-
suppression agents [37]. This may also explain why our es-
timates examining the inﬂuence of these risk factors (as
classiﬁed by medication status) at 1 year post-transplant
tended to be less strongly associated with future morbidity
compared with the presence of risk factors before
E.J. Chow et al. / Biol Blood Marrow Transplant 20 (2014) 794e800 799transplantation or at 2 years. Although we did not observe
a signiﬁcant secular effect for most outcomes we studied,
practice patterns with respect to the monitoring and treat-
ment of cardiovascular risk factors have likely evolved to
some degree over the 20þ years covered by this study [36].
Persistence of these cardiovascular risk factors for longer
periods is clearly important. Long-term HCT survivors who
develop serious cardiovascular complications are more likely
to be smokers and/or have hypertension, dyslipidemia, or
diabetes at last follow-up [7,9,11,13,24]. The combined effect
of cardiotoxic cancer treatment exposures and subsequent
development of conventional cardiovascular risk factors may
be more than additive [38]. However, our study was not
sufﬁciently large enough to reliably assess these interaction
effects. Our results and those of others also demonstrate that
survivors with preexisting cardiovascular conditions are at
greater risk [5,13,37]. Greater cumulative steroid exposure
also has been identiﬁed as a risk factor for persistent diabetes
beyond 2 years [37]. Because the median interval between
transplant and a more serious complication was only 5 years
among our cohort of 2-year survivors, the window of op-
portunity for intervention and control of cardiovascular risk
factors may be limited. Because it also remains difﬁcult for
clinicians to easily predict in advance which patients with
cardiovascular risk factors present 1 year after HCT will have
persistent conditions, more aggressive screening and treat-
ment early on may be indicated. Prospective studies are
needed to determine whether standard interventions pro-
vide the same level of risk reduction as seen in the general
population [36,39].
Ascertainment of late adverse effects many years after
HCT poses a challenge because many survivors may no
longer communicate with or receive care at their original
transplant center [40]. Our use of administrative datasets
minimized the inﬂuence of these response and survival
biases. Although our results are based on patients trans-
planted at 1 center, the broad range of years covered,
ascertainment of outcomes from state registries similar in
design to those available in many other states, and
consideration of multiple exposures similar to those
received by HCT patients elsewhere should permit gener-
alization of our relative risk estimates. Prevalence esti-
mates should be interpreted in the context that regional
differences in cardiovascular health have been well
described, with Washington State in general having
average indices of cardiovascular health compared with
the nation at large [41]. Although our numbers of each
speciﬁc cardiovascular outcome were not large in absolute
terms, limiting our power to detect smaller effects, to our
knowledge this study still represents 1 of the largest
compilation of serious cardiovascular events among HCT
survivors published to date.
In general, the speciﬁcity of hospitalization administra-
tive databases is typically >90%, although sensitivity may be
more variable when compared with chart review [42-48].
Sensitivity for serious acute illness such as stroke and
myocardial infarction typically diagnosed in the hospital
setting is >70% [42-44,47], whereas sensitivity for diagnoses
that may present less acutely such as heart failure can be
more variable [44-46,48]. We addressed this latter limitation
in part by searching for and including additional clinical
heart failure cases (n ¼ 3) identiﬁed in institutional records.
Importantly, misclassiﬁcation of individuals with cardiovas-
cular disease not requiring hospitalization as “unaffected”
would be expected to bias our results toward the null.Other factors not examined in our study such as iron
overload, diet, and physical inactivity may also inﬂuence
subsequent cardiovascular health. Given the relatively young
age of the average transplant recipient, awareness of and
surveillance for premature cardiovascular disease may be
more easily overlooked [16,49]. Efforts to promote smoking
cessation and a healthy lifestyle should be strongly encour-
aged, because these behaviors have been shown to inﬂuence
subsequent cardiovascular morbidity even among HCT sur-
vivors [11]. Although our results indicate that patients with
cardiovascular risk factors merit special attention, particu-
larly those with preexisting, newly developed, and persistent
conditions, the optimal intervention strategy remains an
active area for investigation.ACKNOWLEDGMENTS
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